About Boston Scientific Corp
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.bostonscientific.com/en-US/Home.html
Frequently Asked Questions
What is the 52-week range for BSX?
The 52-week high is $105.65 and the 52-week low is $42.2.
What is the P/E ratio for BSX?
The Price to Earnings (P/E) ratio is 16.93.
What is the dividend yield for BSX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 14.94%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 17.50%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.83.
Analyst Recommendation Trends
Wall Street analyst consensus for BSX over the last few months:
Latest BSX News
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.
Can ISRG Offset China Weakness With Expansion in India and Japan?
Intuitive Surgical sees strong growth in India and improving conditions in Japan helping offset China headwinds as international da Vinci procedures rise 20%.
2 Oversold Stocks Primed to Rebound and 1 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix t
Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029
Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of
2 Profitable Stocks to Research Further and 1 We Avoid
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects
BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.
Cyted Health appoints Thomas West as Board Chair and Robert Epstein as Non-Executive Director to drive US growth
Cyted Health, a leading gastrointestinal molecular diagnostics company, today announced the appointment of Thomas West as Chair of its Board of Directors and Non-Executive Director, and the appointment of Robert Epstein as a Non-Executive Director, to support the company's continued commercial growth across the US and UK.
Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory
Boston Scientific shares slumped 55% over 12 months, driven by weakness in electrophysiology and WATCHMAN. Learn why BSX stock is a buy.
How Big Could BSX Stock's Next Fall Be?
Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.
Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem?
Wells Fargo has put a number on the damage Boston Scientific Corporation’s (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly $300 million in sales and about $0.13 per share in earnings. Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific to $48 from $50 […]
Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating
Oppenheimer has become considerably more cautious on Boston Scientific Corporation (NYSE:BSX), but not cautious enough to abandon its bullish rating. Analyst Suraj Kalia lowered the firm’s price target on Boston Scientific to $65 from $85 on September 21, ahead of the company’s quarterly results, while maintaining an Outperform rating. Kalia is also reducing Oppenheimer’s fiscal […]
FDA Flags Boston Scientific Catheter Recall
Boston Scientific recalls Imager II Angiographic Catheters over tip detachment defect. Learn about patient risks & FDA safety updates.
Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling?
Boston Scientific (BSX) is in focus after initiating a Class II recall of its StoneSmart Connect Console power adapters, affecting 982 units distributed across the US and multiple international markets. Against this recall backdrop, Boston Scientific’s share price has eased 1.7% over the last trading day and is down 6.2% over the past month, while the 1‑year total shareholder return has declined 54.7%, signaling fading momentum despite a small 2.9% gain on a 90‑day share price basis. Scan how...
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
What Do Boston Scientific (BSX) Recall And Executive Retirement Mean For Investors?
Boston Scientific (NYSE: BSX) has started a voluntary global recall of its StoneSmart Connect Console over a power adapter safety issue. The company is informing hospitals and healthcare providers worldwide about the recall and advising on identification and return of affected units. Arthur C. Butcher, who oversees key endoscopy and urology portfolios, has notified Boston Scientific of his decision to retire. The recall of StoneSmart Connect and Arthur C. Butcher's retirement only capture...
Global Remote Cardiac Monitoring Market Size, Share & Trends Analysis 2026-2036 Featuring Profiles of Medtronic, Abbott Labs, Boston Scientific, GE HealthCare Technologies, Philips, Baxter International (Hillrom) and Other Key Players
Growth is driven by rising cardiovascular disease, telehealth adoption, and advances in wearable ECG devices, implantable monitors, AI analytics, and cloud platforms. North America leads, while Asia-Pacific is expected to grow fastest.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Remote Cardiac Monitoring Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Remote Cardiac Monitoring Mark
FDA Classifies Boston Scientific's Recall Of Imager II Angiographic Catheters As Class I Due To Potential Catheter Tip Degradation And Detachment Risk
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/angiographic-catheter-recall-boston-scientific-removes-imager-ii-angiographic-catheters
Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48
Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $50 to $48.
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know
In the closing of the recent trading day, Boston Scientific (BSX) stood at $44.92, denoting a +2.74% move from the preceding trading day.
How Far Can BSX Stock Swing After Losing More Than Half Its Value?
Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.
Ammonix Launches a New AI Architecture for High-Stakes Specialist Agents That Outperform Frontier Models at a Lower Cost
Ammonix today emerged from stealth with a new AI architecture that combines a fast, specialized System One decision-making architecture with a System Two language model for reasoning and interaction.
Cordis wins FDA approval for sirolimus-eluting balloon
The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
2 Value Stocks with Exciting Potential and 1 We Avoid
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
New Strong Sell Stocks for September 21st
AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.
Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65
Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.
GE Aerospace Goes Vertical (Integration)
After decades of spinoffs and separations of various parts, GE Aerospace is now trending toward integration.
Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi
Boston Scientific (BSX) Stock Trades At A Discount On A 55% Slump
Boston Scientific has seen its share price fall sharply over the past year, which naturally raises a question for investors who care about fundamentals. Are the cash flows that the business can generate enough to support where the stock trades today, or has sentiment moved further than the underlying economics justify? The share price has declined 55.4% over the past year, so the recent slide puts the focus squarely on whether that move lines up with the cash that Boston Scientific can...
Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising
Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.
Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls
Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls
Roblox downgraded, Hershey upgraded: Wall Street's top analyst calls
Roblox downgraded, Hershey upgraded: Wall Street's top analyst calls
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
Citi downgrades Boston Scientific on uncertain recovery path
Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.
Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50
Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.
Boston Scientific (BSX) Recalls LUX Dx Cardiac Monitor Over Delayed AF Alerts
Boston Scientific (NYSE:BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and software over atrial fibrillation Burden Alert delays. The recall targets multiple versions of LUX-Dx hardware and associated software that may postpone detection alerts for atrial arrhythmias used in patient monitoring. The US FDA has taken enforcement interest in the action, underscoring regulatory scrutiny of the cardiac monitoring platform and its alert...
US Politicians Are Buying These Two Stocks
An analysis of recent filings from American politicians shows that Accenture (NYSE: ACN) and Boston Scientific (NYSE: BSX) saw an uptick in purchases from notable politicians. Rep. Gilbert Ray Cisneros, Jr. (D-CA) bought Boston Scientific shares, according to a filing earlier this month. The trade was made on August 18, 2026. Rep. Ro Khanna (D-CA) […]
J&J sells Laminar LAA closure assets it bought 3 years ago
The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.
New Strong Sell Stocks for September 16th
AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.
Has BSX Stock Finally Hit Bottom?
Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.
Harbor PanAgora Dynamic Large Cap Core ETF Q2 2026 Portfolio Review
During the second quarter, the Harbor Dynamic Large Cap Core ETF returned 15.76% (NAV), outperforming its benchmark, the S&P 500 Index, which returned 15.20%. Read more here.
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)
Boston Scientific is a leading medical technology company produces high-performance solutions that address patient needs. Read why BSX stock is a strong buy.
Unpacking Q2 Earnings: Boston Scientific (NYSE:BSX) In The Context Of Other Medical Devices & Supplies - Diversified Stocks
Looking back on medical devices & supplies - diversified stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Boston Scientific (NYSE:BSX) and its peers.
Why Pay More For Stryker When BSX Stock Is On Sale?
A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday's story.
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.01% on an annualized basis producing an average annual return of 14.1%. Currently, Boston Scientific has a market capitalization of
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.
Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.
Boston Scientific Corporation (NYSE:BSX) fell 2.3% in early trading on September 8, 2026, after disclosing that an August 25 cyberattack disrupted manufacturing and shipping. The company stated it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. Though operations have since resumed, the incident […]
Is This BSX Stock Pullback Worth The Patience?
Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Boston Scientific fully restores operations after cyberattack
CEO Mike Mahoney gave more details at a Thursday investor conference, saying the company likely lost orders while its plants and distribution centers were shut down.
Boston Scientific: $43 Finally Prices In A Bad 2026
Boston Scientific warns that the cyberattack will hit Q3, but recovery may delayânot loseârevenue. Click here to read this latest analysis of BSX stock.
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Wells Fargo 21st Annual Healthcare Conference September 10, 2026 8:00 AM EDTCompany ParticipantsMichael Mahoney -...
Alpha Buying: 4 Falling Knives Insiders Are Buying
There are dozens of reasons corporate executives sell shares. They may need money to pay taxes, buy a house, settle a divorce, diversify their wealth, or fund a new boat they will use three times before deciding they
Boston Scientific Exec Says Co. Is Re-Evaluating 2027 Framework In Light Of The Cyber Incident And Will Provide A Preview On October; Co. Is Executing A Significant Restructuring Plan That Will Provide Some Financial Benefit
https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/PR377yhtGDwnuWjurFvZmp
BSX Stock: Is It Time To Buy Or Sell Puts?
Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.
2 Healthcare Stocks with Competitive Advantages and 1 We Question
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 25.7% over the past six months while the S&P 500 was up 13.6%.
Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum
MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.
Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.
BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $56
BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $56.
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Boston Scientific Flags Guidance Miss Amid 'Material Impact' From Cybersecurity Incident; Shares Fall
Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater
Boston Scientific misses 2026 guidance after cyberattack
The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St
Boston Scientific Says Cyberattack Will Impact 2026 Results — Says It Is ‘Unlikely’ To Meet Net Sales Growth, EPS Guidance Ranges
Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.
Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers
On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.
Boston Scientific ‘Unlikely to Meet’ Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific Slammed After Cyberattack Hamstrings Sales, Profit
Boston Scientific said Tuesday a cybersecurity incident is likely to have a material impact on its third-quarter and full-year results.
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific expects a 2026 earnings miss after a cyberattack disrupted global operations. Manufacturing and shipping are recovering.
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated?
MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
These S&P500 stocks are moving in today's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Boston Scientific unlikely to meet guidance due to cyberattack
Despite making progress restoring global operations, the device maker said in a securities filing that it is unlikely to meet third-quarter and full-year sales and earnings forecasts.
Boston Scientific Unlikely to Meet Net Sales Guidance as Cybersecurity Incident Disrupts Operations
Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology
Boston Scientific Won’t Meet Guidance Due to Cyberattack
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Boston Scientific on road to recovery following cyberattack
Boston was hit by a cyberattack on 25 August that caused widespread disruption to its global operations.
Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more
These are the stocks posting the largest moves premarket.
Boston Scientific Discloses Its Unlikely To Meet Its FY26 And Q3 Adj EPS And Net Sales Growth Guidance After Cybersecurity Incident
Based on the information currently available as of the date of this Current Report on Form 8-K, the Company has determined that the incident is likely to have a material impact on the Company’s results of operations for
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.
Boston Scientific begins to restore shipping after cyberattack
The company is working through a backlog after the cyberattack hampered manufacturing, order processing and shipping.
Did Recalls And Cyberattack Disruptions Just Shift Boston Scientific's (BSX) Investment Narrative?
In recent weeks, Boston Scientific has faced multiple voluntary global recalls of its Suture Cinch endoscopic devices and ENROUTE Transcarotid Neuroprotection systems, alongside a cybersecurity incident that disrupted operations and led to reduced full‑year 2026 sales and earnings guidance. These simultaneous product quality issues, operational disruptions, and softer demand for key franchises raise fresh questions about the resilience of Boston Scientific’s previously growth-focused...
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.
Protolabs CEO sees big impact from US reshoring despite potential tariffs
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.
Boston Scientific (BSX) Could Be 23% Undervalued After Recalls And Cyber Incident
Boston Scientific (BSX) is back in focus after a series of voluntary global recalls affecting its ENROUTE Transcarotid Neuroprotection Systems and OverStitch Suture Cinch devices, along with a separate cybersecurity incident that has disrupted operations and lowered 2026 guidance. Against this backdrop of recalls and a cybersecurity disruption, Boston Scientific’s recent share price performance has weakened. The stock is at US$48.37 with a year-to-date share price decline of 48.93%, alongside...
Thursday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
Boston Scientific (BSX) Issues Multiple Worldwide Product Recalls
Boston Scientific (NYSE: BSX) has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection System due to risks of arterial sheath tip separation. The company has also begun Class II recalls of certain OverStitch Suture Cinch endoscopic devices, citing deployment and suture cutting failures. These recalls affect widely distributed products and introduce added operational, regulatory and reputational pressures for Boston Scientific in...
FDA Says Aware Boston Scientific Issued Letter To Affected Customers Recommending Unused Infinion CX Leads Be Removed From Where They Are Used/Sold; As Of May 27, 2026, Boston Scientific Reported 1,081 Serious Injuries And No Deaths Associated With Issue Related To Infinion CX Leads
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/spinal-cord-stimulator-recall-boston-scientific-removes-infinion-cx-lead
Boston Scientific (BSX) Stock Looks Cheap After a 55% Slump
Boston Scientific stock has had a steep year, with a sharp share price decline set against valuation checks that point to a potentially cheap entry point based on intrinsic value and market multiples. The stock now screens as undervalued on both a Discounted Cash Flow (DCF) view and on broader valuation metrics, which raises questions about how much of the recent operational setbacks the market has already priced in. Over the past 12 months, Boston Scientific shares have fallen about 55%,...
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-02 | O'Connor Padraig Andrew | -1,171 | - | - |
| 2026-09-02 | O'Connor Padraig Andrew | -567 | $48.37 | $27,426 |
| 2026-09-02 | O'Connor Padraig Andrew | +1,171 | - | - |
| 2026-08-25 | Morano Susan E | +2,040 | $49.2195 | $100,408 |
| 2026-08-11 | Woodworth Emily | +2,930 | $51.19 | $149,987 |
| 2026-08-10 | Monson Jonathan | +9,908 | $50.46 | $499,958 |
| 2026-08-05 | Habiger David C | +2,100 | $47.589 | $99,937 |
| 2026-08-04 | Habiger David C | +140 | $48.5879 | $6,802 |
| 2026-08-03 | Mahoney Michael F | +22,119 | $48.43 | $1,071,223 |
| 2026-08-03 | Mahoney Michael F | +186,240 | $48.3323 | $9,001,408 |
| 2026-08-03 | Habiger David C | +1,042 | $48.0655 | $50,084 |
| 2026-07-31 | Fitzgerald Joseph Michael | +64,198 | $46.73 | $2,999,973 |
| 2026-07-31 | LUDWIG EDWARD J | +5,000 | $45.4799 | $227,400 |
| 2026-07-01 | Monson Jonathan | -2,087 | - | - |
| 2026-07-01 | Monson Jonathan | -1,010 | $43.06 | $43,491 |
| 2026-07-01 | Monson Jonathan | +2,087 | - | - |
| 2026-05-28 | Mahoney Michael F | -386,755 | - | - |
| 2026-05-20 | Pegus Cheryl | +1,770 | $56.49 | $99,987 |
| 2026-05-20 | Habiger David C | +2,250 | $55.9195 | $125,819 |
| 2026-05-20 | LUDWIG EDWARD J | +3,580 | $56.68 | $202,914 |
| 2026-05-19 | Habiger David C | +2,200 | $56.9451 | $125,279 |
| 2026-05-07 | Morano Susan E | +1,281 | - | - |
| 2026-05-07 | Morano Susan E | +3,800 | - | - |
| 2026-05-07 | Mega Jessica L | +3,800 | - | - |
| 2026-05-07 | Weber Christophe Pierre | +2,660 | - | - |
| 2026-05-07 | Weber Christophe Pierre | +1,140 | - | - |
| 2026-05-07 | Weber Christophe Pierre | +1,767 | - | - |
| 2026-05-07 | Pegus Cheryl | +1,281 | - | - |
| 2026-05-07 | Pegus Cheryl | +3,800 | - | - |
| 2026-05-07 | Zane Ellen M | +3,800 | - | - |
| 2026-05-07 | Habiger David C | +3,800 | - | - |
| 2026-05-07 | Smith Cathy R | +2,209 | - | - |
| 2026-05-07 | Smith Cathy R | +3,800 | - | - |
| 2026-05-07 | WICHMANN DAVID S | +3,800 | - | - |
| 2026-05-07 | LUDWIG EDWARD J | +3,800 | - | - |
| 2026-05-02 | O'Connor Padraig Andrew | -1,802 | - | - |
| 2026-05-02 | O'Connor Padraig Andrew | -872 | $56.5 | $49,268 |
| 2026-05-02 | O'Connor Padraig Andrew | +1,802 | - | - |
| 2026-05-02 | Butcher Arthur C | -2,102 | - | - |
| 2026-05-02 | Butcher Arthur C | -1,007 | $56.5 | $56,896 |
| 2026-05-02 | Butcher Arthur C | +2,102 | - | - |
| 2026-03-02 | Weber Christophe Pierre | +323 | - | - |
| 2026-03-02 | Weber Christophe Pierre | +556 | - | - |
| 2026-03-02 | Morano Susan E | +24 | - | - |
| 2026-03-02 | Pegus Cheryl | +24 | - | - |
| 2026-03-02 | Smith Cathy R | +323 | - | - |
| 2026-03-02 | Smith Cathy R | +556 | - | - |
| 2026-03-01 | Woodworth Emily | -838 | - | - |
| 2026-03-01 | Woodworth Emily | -372 | $76.85 | $28,588 |
| 2026-03-01 | Woodworth Emily | +838 | - | - |
| 2026-02-19 | Butcher Arthur C | +6,851 | $75.76 | $519,032 |
| 2026-02-16 | O'Connor Padraig Andrew | -905 | - | - |
| 2026-02-16 | O'Connor Padraig Andrew | -339 | $74.73 | $25,333 |
| 2026-02-16 | O'Connor Padraig Andrew | +905 | - | - |
| 2026-02-16 | O'Sullivan Miriam | -990 | - | - |
| 2026-02-16 | O'Sullivan Miriam | -291 | $74.73 | $21,746 |
| 2026-02-16 | O'Sullivan Miriam | +990 | - | - |
| 2026-02-16 | Woodworth Emily | -637 | - | - |
| 2026-02-16 | Woodworth Emily | -283 | $74.73 | $21,149 |
| 2026-02-16 | Woodworth Emily | +637 | - | - |
| 2026-02-16 | Brown Vance R | -1,839 | - | - |
| 2026-02-16 | Brown Vance R | -890 | $74.73 | $66,510 |
| 2026-02-16 | Brown Vance R | +1,839 | - | - |
| 2026-02-16 | Monson Jonathan | -990 | - | - |
| 2026-02-16 | Monson Jonathan | -440 | $74.73 | $32,881 |
| 2026-02-16 | Monson Jonathan | +990 | - | - |
| 2026-02-16 | Butcher Arthur C | -2,546 | - | - |
| 2026-02-16 | Butcher Arthur C | -1,229 | $74.73 | $91,843 |
| 2026-02-16 | Butcher Arthur C | +2,546 | - | - |
| 2026-02-16 | Mahoney Michael F | -16,265 | - | - |
| 2026-02-16 | Mahoney Michael F | -7,865 | $74.73 | $587,751 |
| 2026-02-16 | Mahoney Michael F | +16,265 | - | - |
| 2026-02-16 | Fitzgerald Joseph Michael | -3,960 | - | - |
| 2026-02-16 | Fitzgerald Joseph Michael | -1,806 | $74.73 | $134,962 |
| 2026-02-16 | Fitzgerald Joseph Michael | +3,960 | - | - |
| 2026-02-14 | O'Connor Padraig Andrew | -1,190 | - | - |
| 2026-02-14 | O'Connor Padraig Andrew | -449 | $74.73 | $33,554 |
| 2026-02-14 | O'Connor Padraig Andrew | +1,190 | - | - |
| 2026-02-14 | O'Sullivan Miriam | -1,124 | - | - |
| 2026-02-14 | O'Sullivan Miriam | -329 | $74.73 | $24,586 |
| 2026-02-14 | O'Sullivan Miriam | +1,124 | - | - |
| 2026-02-14 | Woodworth Emily | -661 | - | - |
| 2026-02-14 | Woodworth Emily | -296 | $74.73 | $22,120 |
| 2026-02-14 | Woodworth Emily | +661 | - | - |
| 2026-02-14 | Brown Vance R | -1,851 | - | - |
| 2026-02-14 | Brown Vance R | -895 | $74.73 | $66,883 |
| 2026-02-14 | Brown Vance R | +1,851 | - | - |
| 2026-02-14 | Monson Jonathan | -1,058 | - | - |
| 2026-02-14 | Monson Jonathan | -470 | $74.73 | $35,123 |
| 2026-02-14 | Monson Jonathan | +1,058 | - | - |
| 2026-02-14 | Butcher Arthur C | -3,173 | - | - |
| 2026-02-14 | Butcher Arthur C | -1,535 | $74.73 | $114,711 |
| 2026-02-14 | Butcher Arthur C | +3,173 | - | - |
| 2026-02-14 | Mahoney Michael F | -16,524 | - | - |
| 2026-02-14 | Mahoney Michael F | -7,990 | $74.73 | $597,093 |
| 2026-02-14 | Mahoney Michael F | +16,524 | - | - |
| 2026-02-14 | Fitzgerald Joseph Michael | -4,362 | - | - |
| 2026-02-14 | Fitzgerald Joseph Michael | -1,990 | $74.73 | $148,713 |
| 2026-02-14 | Fitzgerald Joseph Michael | +4,362 | - | - |
| 2026-02-13 | O'Connor Padraig Andrew | -500 | - | - |
| 2026-02-13 | O'Connor Padraig Andrew | -199 | $74.73 | $14,871 |
| 2026-02-13 | O'Connor Padraig Andrew | +500 | - | - |
| 2026-02-13 | O'Sullivan Miriam | -588 | - | - |
| 2026-02-13 | O'Sullivan Miriam | -200 | $74.73 | $14,946 |
| 2026-02-13 | O'Sullivan Miriam | +588 | - | - |
| 2026-02-13 | Woodworth Emily | -1,413 | - | - |
| 2026-02-13 | Woodworth Emily | -690 | $74.73 | $51,564 |
| 2026-02-13 | Woodworth Emily | +1,413 | - | - |
| 2026-02-13 | Brown Vance R | -1,118 | - | - |
| 2026-02-13 | Brown Vance R | -12,792 | $74.73 | $955,946 |
| 2026-02-13 | Brown Vance R | +1,118 | - | - |
| 2026-02-13 | Brown Vance R | +14,804 | - | - |
| 2026-02-13 | Brown Vance R | +14,804 | - | - |
| 2026-02-13 | Monson Jonathan | -1,766 | - | - |
| 2026-02-13 | Monson Jonathan | -788 | $74.73 | $58,887 |
| 2026-02-13 | Monson Jonathan | +1,766 | - | - |
| 2026-02-13 | Butcher Arthur C | -2,237 | - | - |
| 2026-02-13 | Butcher Arthur C | -25,150 | $74.73 | $1,879,460 |
| 2026-02-13 | Butcher Arthur C | +2,237 | - | - |
| 2026-02-13 | Butcher Arthur C | +25,380 | - | - |
| 2026-02-13 | Butcher Arthur C | +25,380 | - | - |
| 2026-02-13 | Mahoney Michael F | -8,832 | - | - |
| 2026-02-13 | Mahoney Michael F | -132,099 | $74.73 | $9,871,758 |
| 2026-02-13 | Mahoney Michael F | +8,832 | - | - |
| 2026-02-13 | Mahoney Michael F | +132,190 | - | - |
| 2026-02-13 | Mahoney Michael F | +132,190 | - | - |
| 2026-02-13 | Fitzgerald Joseph Michael | -2,797 | - | - |
| 2026-02-13 | Fitzgerald Joseph Michael | -33,104 | $74.73 | $2,473,862 |
| 2026-02-13 | Fitzgerald Joseph Michael | +2,797 | - | - |
| 2026-02-13 | Fitzgerald Joseph Michael | +34,898 | - | - |
| 2026-02-13 | Fitzgerald Joseph Michael | +34,898 | - | - |
| 2026-02-12 | O'Connor Padraig Andrew | +11,939 | - | - |
| 2026-02-12 | O'Connor Padraig Andrew | +5,059 | - | - |
| 2026-02-12 | O'Connor Padraig Andrew | -1,058 | - | - |
| 2026-02-12 | O'Connor Padraig Andrew | -457 | $74.12 | $33,873 |
| 2026-02-12 | O'Connor Padraig Andrew | +1,058 | - | - |
| 2026-02-12 | O'Sullivan Miriam | +11,143 | - | - |
| 2026-02-12 | O'Sullivan Miriam | +4,722 | - | - |
| 2026-02-12 | O'Sullivan Miriam | -961 | - | - |
| 2026-02-12 | O'Sullivan Miriam | -338 | $74.12 | $25,053 |
| 2026-02-12 | O'Sullivan Miriam | +961 | - | - |
| 2026-02-12 | Woodworth Emily | +5,584 | - | - |
| 2026-02-12 | Woodworth Emily | +6,071 | - | - |
| 2026-02-12 | Woodworth Emily | -481 | - | - |
| 2026-02-12 | Woodworth Emily | -242 | $74.12 | $17,937 |
| 2026-02-12 | Woodworth Emily | +481 | - | - |
| 2026-02-12 | Brown Vance R | +17,510 | - | - |
| 2026-02-12 | Brown Vance R | +7,420 | - | - |
| 2026-02-12 | Brown Vance R | -1,442 | - | - |
| 2026-02-12 | Brown Vance R | -488 | $74.12 | $36,171 |
| 2026-02-12 | Brown Vance R | +1,442 | - | - |
| 2026-02-12 | Monson Jonathan | +27,857 | - | - |
| 2026-02-12 | Monson Jonathan | +11,805 | - | - |
| 2026-02-12 | Monson Jonathan | -1,154 | - | - |
| 2026-02-12 | Monson Jonathan | -573 | $74.12 | $42,471 |
| 2026-02-12 | Monson Jonathan | +1,154 | - | - |
| 2026-02-12 | Butcher Arthur C | +35,817 | - | - |
| 2026-02-12 | Butcher Arthur C | +15,178 | - | - |
| 2026-02-12 | Butcher Arthur C | -2,692 | - | - |
| 2026-02-12 | Butcher Arthur C | -1,302 | $74.12 | $96,504 |
| 2026-02-12 | Butcher Arthur C | +2,692 | - | - |
| 2026-02-12 | Mahoney Michael F | +131,329 | - | - |
| 2026-02-12 | Mahoney Michael F | +55,652 | - | - |
| 2026-02-12 | Mahoney Michael F | -13,704 | - | - |
| 2026-02-12 | Mahoney Michael F | -6,626 | $74.12 | $491,119 |
| 2026-02-12 | Mahoney Michael F | +13,704 | - | - |
| 2026-02-12 | Fitzgerald Joseph Michael | +43,776 | - | - |
| 2026-02-12 | Fitzgerald Joseph Michael | +18,550 | - | - |
| 2026-02-12 | Fitzgerald Joseph Michael | -3,462 | - | - |
| 2026-02-12 | Fitzgerald Joseph Michael | -1,612 | $74.12 | $119,481 |
| 2026-02-12 | Fitzgerald Joseph Michael | +3,462 | - | - |
| 2026-02-02 | Mahoney Michael F | -49,407 | - | - |
| 2026-02-02 | Mahoney Michael F | -46,347 | - | - |
| 2026-02-02 | Mahoney Michael F | -159,701 | $93.4905 | $14,930,526 |
| 2026-02-02 | Mahoney Michael F | -1,200 | $94.0567 | $112,868 |
| 2026-02-02 | Mahoney Michael F | +46,347 | $27.09 | $1,255,540 |
| 2026-02-02 | Mahoney Michael F | +49,407 | $24.55 | $1,212,942 |
| 2025-12-01 | Butcher Arthur C | -3,177 | - | - |
| 2025-12-01 | Butcher Arthur C | -6,175 | - | - |
| 2025-12-01 | Butcher Arthur C | -1,009 | - | - |
| 2025-12-01 | Butcher Arthur C | -6,952 | - | - |
| 2025-12-01 | Butcher Arthur C | -17,313 | $101.5531 | $1,758,189 |
| 2025-12-01 | Butcher Arthur C | +1,009 | $17.26 | $17,415 |
| 2025-12-01 | Butcher Arthur C | +3,177 | $22.71 | $72,150 |
| 2025-12-01 | Butcher Arthur C | +6,175 | $24.55 | $151,596 |
| 2025-12-01 | Butcher Arthur C | +6,952 | $27.09 | $188,330 |
| 2025-11-28 | O'Sullivan Miriam | -260 | - | - |
| 2025-11-14 | Fitzgerald Joseph Michael | -9,610 | - | - |
| 2025-11-12 | Fitzgerald Joseph Michael | -690 | - | - |
| 2025-11-06 | Zane Ellen M | -12,891 | $98.2839 | $1,266,978 |
| 2025-11-03 | Fitzgerald Joseph Michael | -50,000 | - | - |
| 2025-11-03 | Fitzgerald Joseph Michael | -29,472 | $99.1414 | $2,921,895 |
| 2025-11-03 | Fitzgerald Joseph Michael | -16,928 | $99.7607 | $1,688,749 |
| 2025-11-03 | Fitzgerald Joseph Michael | -3,600 | $100.7481 | $362,693 |
| 2025-11-03 | Fitzgerald Joseph Michael | +50,000 | $26.15 | $1,307,500 |
| 2025-10-30 | Mahoney Michael F | -149,992 | - | - |
| 2025-10-29 | Mahoney Michael F | +73,996 | - | - |
| 2025-10-29 | Mahoney Michael F | +88,197 | - | - |
| 2025-10-29 | Zane Ellen M | +12,891 | - | - |
| 2025-10-28 | Zane Ellen M | -2,901 | $102.2402 | $296,599 |
| 2025-10-27 | Zane Ellen M | -9,990 | $101.1312 | $1,010,301 |